Immunovant, Inc. news

A server-rendered, paginated timeline of the latest available company news.

Kuehn Law Encourages Investors of Immunovant, Inc. to Contact Law Firm
NEW YORK, July 20, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Immunovant, Inc. (NASDAQ: IMVT) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing. Shareholders may be entitled to damages and corporate governance reforms. If you are a long-term IMVT stockholder please contact Justin Kuehn, Esq. by email at justin@kuehn.law or call (833) 672-0814. The consult
Globe Newswire · Jul 20, 2026
Immunovant Announces Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED)
* Phase 3 studies of batoclimab in thyroid eye disease (TED) each failed to meet their primary endpoint; safety results were consistent with previous findings * Patients in the TED studies demonstrated greater levels of proptosis improvement from baseline after the initial 12-week high-dose period than after the following 12-week low-dose period, supporting the benefit of deeper IgG suppression. The hyperthyroid patients in the TED studies showed similar response rates of thyroid hormone normali
Globe Newswire · Apr 2, 2026

Kuehn Law Encourages Investors of Immunovant, Inc. to Contact Law Firm